DrugPatentWatch Database Preview
KERENDIA Drug Patent Profile
Email this page to a colleague
Which patents cover Kerendia, and when can generic versions of Kerendia launch?
Kerendia is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.
This drug has fifty-four patent family members in forty-two countries.
The generic ingredient in KERENDIA is finerenone. One supplier is listed for this compound. Additional details are available on the finerenone profile page.
DrugPatentWatch® Generic Entry Outlook for Kerendia
Kerendia will be eligible for patent challenges on July 9, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 12, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for KERENDIA
| International Patents: | 54 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in KERENDIA? | KERENDIA excipients list |
| DailyMed Link: | KERENDIA at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for KERENDIA
Generic Entry Date for KERENDIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for KERENDIA
| Drug Class | Nonsteroidal Mineralocorticoid-Receptor Antagonist |
| Mechanism of Action | Mineralocorticoid Receptor Antagonists |
US Patents and Regulatory Information for KERENDIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | KERENDIA | finerenone | TABLET;ORAL | 215341-001 | Jul 9, 2021 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Bayer Hlthcare | KERENDIA | finerenone | TABLET;ORAL | 215341-002 | Jul 9, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Bayer Hlthcare | KERENDIA | finerenone | TABLET;ORAL | 215341-001 | Jul 9, 2021 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for KERENDIA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5367586 | ⤷ Try it Free |
| South Africa | 200905730 | ⤷ Try it Free |
| Cuba | 20090148 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
